Subtopic Deep Dive
Synthetic Lethality in DNA Repair
Research Guide
What is Synthetic Lethality in DNA Repair?
Synthetic lethality in DNA repair refers to the genetic interaction where PARP inhibition selectively kills cancer cells deficient in homologous recombination (HR) due to BRCA mutations or HR deficiency (HRD), exploiting their reliance on PARP for single-strand break repair.
This concept underpins PARP inhibitor (PARPi) therapy, first demonstrated clinically with olaparib in BRCA-mutated tumors (Fong et al., 2009, 3582 citations). Screens identify synthetic lethal partners beyond BRCA, targeting alternative repair pathways in HRD cancers (Lord and Ashworth, 2017, 2681 citations). Over 10 key papers from 2008-2021 detail clinical responses and mechanisms.
Why It Matters
Synthetic lethality enables precise targeting of HRD tumors beyond BRCA1/2 mutations, achieving durable responses in ovarian, prostate, and breast cancers (Fong et al., 2009; Mateo et al., 2015). It expands PARPi use to 50% of high-grade serous ovarian cancers with HRD signatures, improving progression-free survival when combined with bevacizumab (Ray-Coquard et al., 2019). Lord and Ashworth (2017) highlight its role in translating genetic concepts to clinic, guiding patient selection via genomic profiling.
Key Research Challenges
Identifying non-BRCA partners
Genetic screens must pinpoint synthetic lethal genes beyond BRCA1/2 in diverse HRD contexts. CRISPR-based approaches reveal context-specific vulnerabilities but require validation (Lord and Ashworth, 2017). Computational models struggle with pathway redundancy (Curtin, 2012).
Overcoming PARPi resistance
Tumors restore HR via reversion mutations or alternative repair, limiting long-term efficacy. Clinical data show resistance in BRCA carriers correlating with platinum-free intervals (Fong et al., 2010). Combination strategies target multiple lesions (Pilié et al., 2018).
HRD biomarker development
Genomic scarring signatures predict PARPi response but vary across cancer types. Validation in prostate and ovarian cohorts remains inconsistent (Mateo et al., 2015). Functional assays complement static markers (Ashworth, 2008).
Essential Papers
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord, Alan Ashworth · 2017 · Science · 2.7K citations
PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a...
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · 2015 · New England Journal of Medicine · 2.1K citations
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (...
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · 2019 · New England Journal of Medicine · 1.9K citations
In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, ...
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · 2021 · New England Journal of Medicine · 1.5K citations
Among patients with high-risk, HER2-negative early breast cancer and germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local trea...
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilié, Chad Tang, Gordon B. Mills et al. · 2018 · Nature Reviews Clinical Oncology · 1.2K citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo, Cristiana Sessa, Andreas du Bois et al. · 2019 · Annals of Oncology · 1.1K citations
Reading Guide
Foundational Papers
Start with Fong et al. (2009) for first clinical proof of PARPi synthetic lethality in BRCA carriers, then Ashworth (2008) for DNA repair concepts, and Fong et al. (2010) for ovarian response data.
Recent Advances
Study Lord and Ashworth (2017) for clinic translation, Mateo et al. (2015) for prostate applications, and Ray-Coquard et al. (2019) for HRD ovarian maintenance therapy.
Core Methods
Core techniques include PARP trapping, HRD genomic signatures, CRISPR lethality screens, and platinum sensitivity as proxy for HR status (Lord and Ashworth, 2017; Curtin, 2012).
How PapersFlow Helps You Research Synthetic Lethality in DNA Repair
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'synthetic lethal partners BRCA PARP inhibition', retrieving Fong et al. (2009) and Lord and Ashworth (2017); citationGraph maps 3582 citations from Fong to identify HRD extensions; findSimilarPapers uncovers Curtin (2012) on repair dysregulation.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mechanisms from Fong et al. (2010), verifies synthetic lethality claims via verifyResponse (CoVe) against Lord and Ashworth (2017), and runs PythonAnalysis on HRD signature data for statistical correlation (e.g., platinum-free interval vs. response); GRADE grading scores clinical evidence as high for BRCA carriers.
Synthesize & Write
Synthesis Agent detects gaps in non-BRCA partners via contradiction flagging across Pilié et al. (2018) and Mateo et al. (2015); Writing Agent uses latexEditText, latexSyncCitations for Fong et al., and latexCompile to generate review sections; exportMermaid diagrams DNA repair pathways and lethality interactions.
Use Cases
"Analyze survival data from olaparib trials in HRD prostate cancer"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Mateo et al. 2015 response rates) → outputs Kaplan-Meier plots and p-values.
"Draft LaTeX review on synthetic lethality mechanisms"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Fong 2009, Lord 2017) + latexCompile → outputs compiled PDF with cited figures.
"Find code for CRISPR screens in PARPi synthetic lethality"
Research Agent → paperExtractUrls (Lord 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs screen analysis pipelines.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'HRD synthetic lethality', chains citationGraph to Pilié et al. (2018), and generates structured report with GRADE scores. DeepScan applies 7-step CoVe verification to Fong et al. (2009) abstracts, checkpointing mechanisms against Curtin (2012). Theorizer builds models of repair pathway interactions from Ashworth (2008) and recent trials.
Frequently Asked Questions
What defines synthetic lethality in PARP inhibition?
It is the selective death of HR-deficient cells when PARP is inhibited, as BRCA-mutated tumors rely on PARP for repair (Lord and Ashworth, 2017; Fong et al., 2009).
What methods identify synthetic lethal partners?
CRISPR screens and genetic interaction mapping detect partners beyond BRCA; clinical validation uses olaparib response in HRD tumors (Fong et al., 2010; Ashworth, 2008).
What are key papers on this topic?
Foundational: Fong et al. (2009, 3582 citations), Ashworth (2008, 843 citations); Recent: Lord and Ashworth (2017, 2681 citations), Mateo et al. (2015, 2133 citations).
What open problems exist?
Resistance mechanisms, non-BRCA HRD biomarkers, and pathway redundancy challenge broad application (Pilié et al., 2018; Curtin, 2012).
Research PARP inhibition in cancer therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Synthetic Lethality in DNA Repair with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the PARP inhibition in cancer therapy Research Guide